No title
Background: The European ALLTogether protocol for childhood acute lymphoblastic leukemia, initiated in Sweden 2019, introduced earlier asparaginase during induction, dexamethasone instead of prednisone for all patients, and omitted anthracyclines from low-risk induction to reduce treatment-related toxicity. Consolidation-1 was based on the Induction 1B-phase developed by the BFM-group, replacing m
